Phase 1 Ovarian Cancer trials recruiting now

All Ovarian Cancer trials, every phase

Other phases for Ovarian Cancer

Phase 1 Ovarian Cancer trials

• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
  NCT07189871 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
  NCT05746897 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Phase 1 Study of LNCB74 in Advanced Solid Tumors
  NCT06774963 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
  NCT06508307 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
  NCT06586957 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 38 locations
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
  NCT06738966 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
  NCT06873555 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
  NCT05377996 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
  NCT05740956 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Study of MT-4561 in Patients With Various Advanced Solid Tumors
  NCT06943521 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
  NCT05877599 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 23 locations
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
  NCT06395519 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
  NCT06051695 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
  NCT07612891 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
  NCT07610798 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
  NCT07613723 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
  NCT04503265 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• AOH1996 for the Treatment of Refractory Solid Tumors
  NCT05227326 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• APG-2449 in Patients With Advanced Solid Tumors
  NCT03917043 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
  NCT02830724 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
  NCT05000294 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
  NCT00722228 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
  NCT04752826 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
  NCT07410494 · Phase: Phase 1, Phase 2 · Ages: 8 Years to 85 Years · Sex: All (male and female) · 3 locations
• CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
  NCT07181720 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
  NCT06337084 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
  NCT07517198 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
  NCT06617169 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
  NCT07410676 · Phase: Phase 1, Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
  NCT06926075 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
  NCT05983432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 117 locations
• FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
  NCT07216105 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
  NCT04038619 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
  NCT06303505 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 29 locations
• First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
  NCT05104515 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 8 locations
• IDOV-Immune for Advanced Solid Tumors
  NCT06910657 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
  NCT04847063 · Phase: Phase 1 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• Lead-212 PSV359 Therapy for Patients With Solid Tumors
  NCT06710756 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 22 locations
• Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
  NCT06293898 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
  NCT05735080 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
  NCT07424547 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
  NCT06307249 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
  NCT06412510 · Phase: Phase 1, Phase 2 · Ages: 65 Years and older · Sex: All (male and female) · 1 location
• SL-28 for Advanced Solid Tumours
  NCT07341737 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
  NCT05799274 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
  NCT06582017 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
  NCT07444814 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
  NCT05427487 · Phase: Phase 1 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 3 locations
• Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
  NCT06545942 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
  NCT06430541 · Phase: Phase 1 · Ages: 21 Years and older · Sex: Female · 2 locations
• Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
  NCT07524322 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT06666270 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
  NCT06799637 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
  NCT05568680 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
  NCT04969315 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations
• Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
  NCT07064018 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.